Disclosed herein are novel dual-target compounds that bind at both the mu-opioid receptor (MOR) and dopamine D3receptors (D3R) to provide MOR-mediated analgesia, while minimizing addictive liability through D3R antagonism/partial agonism. The novel compounds are useful in the treatment of pain and substance use disorder.
本文披露了一种新型的双靶点化合物,它们能够同时结合μ-阿片受体(MOR)和
多巴胺D3受体(D3R),从而通过D3R的拮抗/部分激动作用来最小化成瘾性,同时提供MOR介导的镇痛作用。这种新型化合物可用于治疗疼痛和物质使用障碍。